FOLH1 and xerostomia: However, there are some side effects documented with PSMA-targeted radioligand therapy; most commonly xerostomia (47–87%) in which several patients required salivary substitute gel, and in the case of hematotoxicity, mainly thrombocytopenia in 17–40% of the patients treated with [177Lu]Lu-PSMA-617 therapy [9,11].